Top Analysts Recommend 3 Stocks to Buy Now: WIX, DDOG, and CTNM

Three stocks to buy now, according to top analysts, are Wix.com Ltd. (WIX), Datadog (DDOG), and Continuum Therapeutics (CTNM). WIX has a 57.28% upside, DDOG has a 25.19% upside, and CTNM has a 171.6% upside. These stocks received new Buy ratings and have significant potential for growth. TipRanks' Analyst Top Stocks tool can help investors find more stocks like these.

Three stocks have been highlighted by top analysts as strong buys with substantial upside potential. These stocks include Wix.com Ltd. (WIX), Datadog (DDOG), and Continuum Therapeutics (CTNM). Each stock has received new Buy ratings and offers significant growth prospects.

Wix.com Ltd. (WIX), an Israeli software company that provides a cloud-based web development platform, has been rated a Buy by 15 out of 17 top analysts. The stock has a price target of $200, implying an upside of about 57.28% [1]. This growth is supported by the company's strong financial health, with $551.25 million in levered free cash flow over the last twelve months. Wix has also expanded its share repurchase program by $200 million, increasing the total potential repurchase amount to $500 million, reflecting confidence in its financial performance [2].

Datadog (DDOG), a cloud platform that helps businesses monitor and track their applications, servers, and data, has been rated a Buy by 25 out of 29 top analysts. The stock has a price target of $170, indicating an upside of about 25.19% [1]. Datadog reported robust sales growth in its second quarter 2025 earnings, with sales of $826.76 million and updated revenue guidance of $847–851 million for the third quarter and $3.31–3.32 billion for the full year. However, the company's net income fell sharply, highlighting challenges in converting top-line expansion into profitability [3].

Continuum Therapeutics (CTNM), a clinical-stage biotech company developing oral therapies for neurological, inflammatory, and immune-related diseases, has been rated a Buy by all three top analysts covering the stock. The stock has a price target of $21, implying an upside of about 171.6% [1]. This significant upside potential is driven by the company's innovative pipeline of therapies and the growing demand for treatments in these areas.

Investors interested in finding more stocks with similar potential can use TipRanks' Analyst Top Stocks tool, which provides a real-time list of all stocks recently rated by top-ranking analysts [1].

References:
[1] https://www.tipranks.com/news/3-best-stocks-to-buy-now-8-19-2025-according-to-top-analysts
[2] https://www.ainvest.com/news/wix-expands-share-repurchase-program-200-million-boosting-total-500-million-2508/
[3] https://simplywall.st/stocks/us/software/nasdaq-ddog/datadog/news/can-datadogs-ddog-margin-squeeze-redefine-its-path-from-grow